Opzelura
Eczema Treatments
Opzelura
Eczema Treatments

Opzelura

Use Opzelura® (ruxolitinib cream) as prescribed to help treat eczema (atopic dermatitis) by targeting inflammatory pathways in the skin that drive itching, redness, and irritation—without the use of topical steroids.
Opzelura is a topical Janus kinase (JAK) inhibitor that targets inflammation at the cellular level. It reduces redness, itching, and lesions in mild to moderate eczema.
It is prescribed for individuals with mild to moderate eczema who have not responded well to topical steroids or other treatments.
Improvement is often seen within 1–2 weeks, with continued improvement over several months of use.
Opzelura is prescribed for adults and adolescents with mild to moderate eczema who are not adequately controlled with topical therapies or when topical steroids are not suitable. It may be used on sensitive areas, including the face and skin folds, under clinician guidance. See pricing details here.

Real patients, real results

How effective is Opzelura

Clinically proven results

Rapid itch relief and clearer skin with significant improvement in eczema symptoms.*
Clinical studies show that Opzelura can reduce itching as early as Day 2, with continued improvement in redness, inflammation, and overall skin appearance over time.
*In clinical trials, many patients using Opzelura achieved clear or almost clear skin and meaningful itch reduction within 8 weeks compared to placebo.
Opzelura should be used only as prescribed. For more details, see Important Safety Information.

How DermOnDemand Works

Common Question

Common side effects include mild redness or irritation at the application site. Rarely, it may affect immune function with prolonged use.
Yes, Opzelura can be used long-term under the guidance of your doctor for chronic eczema management.